文献速递冠心病心力衰竭与心肌病

静脉右雷佐生治疗出血性心肌梗死:SHIELD-MI研究

Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study.
PubMed 文献 · Eur Heart J · 2026-08-31

SHIELD-MI是一项单中心、非随机、安慰剂对照、序贯队列IIa期研究,纳入50例再灌注STEMI患者(25例静脉右雷佐生,25例匹配安慰剂),评估早期LVEF和心肌内出血体积。右雷佐生组LVEF更高(39.8±7.7% vs 34.7±10.1%,P=0.048),IMH体积更低(2.0±3.4% LV vs 6.3±6.0% LV,P=0.004),梗死面积更小,出血性MI发生率更低(24% vs 64%,P=0.010),无药物相关严重不良事件。

要点

  • 静脉右雷佐生可降低再灌注STEMI患者心肌内出血体积和梗死面积。
  • 右雷佐生组LVEF更高,出血性MI发生率更低,无药物相关严重不良事件。
  • 探索性 findings 提示IMH为候选治疗靶点,需随机试验验证。

核心结论

  • 围术期静脉右雷佐生与更低的IMH和梗死面积及更高的LVEF相关,无安全性担忧。
  • 探索性发现提示IMH是值得随机试验验证的候选治疗靶点。

研究设计与样本

  • SHIELD-MI为单中心、非随机、安慰剂对照、序贯队列IIa期研究,参与者和CMR核心实验室对治疗设盲。
  • 25例患者接受静脉右雷佐生250 mg(PCI前及之后4、8、12小时),从78例安慰剂治疗患者中选取25例对照,按总缺血时间、罪犯血管区域和PCI前闭塞状态匹配。
  • 匹配分析队列共50例,主要终点为48-72小时CMR测量的LVEF和IMH体积。

主要发现

  • 右雷佐生组LVEF为39.8±7.7%,对照组为34.7±10.1%(P=0.048)。
  • 右雷佐生组IMH体积为2.0±3.4% LV,对照组为6.3±6.0% LV(P=0.004)。
  • 右雷佐生组梗死面积为29.1±13.1% LV,对照组为43.8±18.6% LV(P=0.002)。
  • 出血性MI发生于右雷佐生组6/25(24%)和对照组16/25(64%)(P=0.010)。
  • 未观察到药物相关严重不良事件。

临床怎么用

  • 围术期静脉右雷佐生可能减轻再灌注STEMI患者的出血性心肌损伤并改善早期心室功能。
  • 当前证据为探索性,尚不能常规推荐使用,需等待随机试验验证。

局限性

  • 单中心、非随机、序贯队列设计,样本量小(匹配队列n=50)。
  • 对照从78例安慰剂治疗患者中选取并匹配,可能存在残余混杂。
  • 结果为探索性,需随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Intramyocardial hemorrhage (IMH) after reperfused ST-elevation myocardial infarction (STEMI) is associated with adverse outcomes, yet no therapy specifically targets it. Dexrazoxane (DXZ) may mitigate iron-mediated injury from IMH. METHODS: SHIELD-MI was a single-center, non-randomized, placebo-controlled, sequential-cohort phase IIa study with participants and the cardiac MRI (CMR) core laboratory blinded to treatment. Twenty-five patients received intravenous DXZ 250 mg before primary PCI and at 4, 8, and 12 h thereafter. Twenty-five comparators, selected from 78 placebo-treated patients, were matched on total ischemic time, culprit territory, and pre-PCI occlusion status. Primary endpoints were left ventricular ejection fraction (LVEF) and IMH volume on CMR at 48-72 h, evaluating early ventricular function and hemorrhagic myocardial injury after reperfusion. RESULTS: In the matched analytic cohort (n=50), LVEF was higher in patients receiving DXZ (39.8±7.7% vs. 34.7±10.1%; P=0.048), permitting formal testing of IMH volume, which was lower with DXZ (2.0±3.4% LV vs. 6.3±6.0% LV; P=0.004). The prespecified fixed-sequence criterion was therefore met at both steps. Infarct size was lower with DXZ (29.1±13.1% LV vs. 43.8±18.6% LV; P=0.002). Hemorrhagic MI occurred in 6/25 (24%) versus 16/25 (64%) participants (P=0.010). No drug-related serious adverse events were observed. CONCLUSIONS: Peri-procedural intravenous DXZ was associated with lower IMH and infarct size and higher LVEF, without safety concerns. These exploratory findings identify IMH as a candidate therapeutic target warranting a randomized trial.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Vora KP, Bhatt K, Doshi S, et al. Intravenous dexrazoxane for haemorrhagic myocardial infarction: the SHIELD-MI study. Eur Heart J. 2026. PMID: 42670881. doi:10.1093/eurheartj/ehag715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。